Received: 22 October 2020
Accepted: 13 January 2021
First Online: 15 February 2021
Ethics approval and consent to participate
: The study protocol was approved by the local ethics committees and was conducted in accordance with Directive 2001/20/EC, as well as Good Clinical Practices (I.C.H. version 4 of May 1, 1996 and Decision of November 24, 2006) and the declaration of Helsinki.
: All authors have reviewed and approved the manuscript and are willing to attest to their qualifications as authors, disclose potential conflicts of interest, and release copyright should the manuscript be accepted for publication.
: Dr. Mebazaa reports personal fees from Orion, Servier, Otsuka, Philips, Sanofi, Adrenomed, Epygon and Fire 1 and grants and personal fees from 4TEEN4, Abbott and Sphingotec. BD and ABl were invited to meetings in Hennigsdorf by 4TEEN4 Pharmaceuticals GmbH. KS and ABe are employees of 4TEEN4 Pharmaceuticals GmbH. BC served as a member of an advisory board for Roche Diagnostic. ML reports research support from sphingotec, lecture fees from Baxter and Fresenius, consulting fees from Novartis. Other authors declared no potential conflicts of interest with respect to the research authorship and/or publication of this article. 4TEEN4 Pharmaceuticals GmbH holds patent rights on the DPP3 biomarker and humanized antibody Procizumab. This does not alter our adherence to Critical Care Medicine policies on sharing data and materials.